A Phase I/II Study of the Pharmacokinetics, Tolerability and Safety of Administration of VX-853 [timcodar] to Patients Receiving Single Agent Therapy With Doxorubicin HCI
Phase of Trial: Phase I/II
Latest Information Update: 21 Sep 2016
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Timcodar (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 20 Sep 2005 New trial record.